Skip to content
Markets

Novartis Raises Its Profit Outlook Despite a $1.9bn Writedown on Del-desiran

Novartis raised its 2026 profit guidance as Q3 core operating income rose 10% to $6.04bn, beating the $5.51bn expected, even as a $1.9bn del-desiran writedown cut reported profit by 59%.

The Novartis logo on the white Banting 1 building on the Novartis Campus in Basel, with trees and older campus buildings below a blue sky.
Photo: Novartis

Novartis raised its full-year profit guidance on Tuesday after third-quarter core operating income rose 10% at constant currencies to $6.04bn, well ahead of the $5.51bn analysts expected, as Kisqali and newer drugs outran generic competition. A $1.9bn writedown on del-desiran, the muscle-disease drug that failed in September, cut reported operating income by 59%.

A profit beat on in-line sales

Net sales were $14.52bn, up 4% both at constant currencies and in dollars, matching the $14.5bn forecast in the consensus collected by Newsquawk. The surprise came lower down: the core operating margin widened by 2.3 percentage points to 41.6%, and core earnings per share of $2.46 beat the $2.28 expected.

Volume growth added 14 percentage points to sales, while generic competition took away 9 points and lower prices one more. Free cash flow fell 18% to $5.1bn.

The new 2026 guidance

  • Core operating income: in line with last year or up by a low single-digit percentage, from a low single-digit decline before
  • Net sales: growth by a low single-digit percentage, unchanged
  • Currency: a positive effect of about one percentage point on both if late-October exchange rates hold

Chief executive Vas Narasimhan said priority brands and launches more than offset generic erosion, showing "the replacement power of the business".

Portrait of Novartis Chief Executive Vas Narasimhan in a light blue shirt, outdoors with trees blurred behind him.
Portrait of Novartis Chief Executive Vas Narasimhan in a light blue shirt, outdoors with trees blurred behind him. Photo: Novartis

Novartis: share price, chart and news

The brands doing the work

Breast cancer drug Kisqali added the most growth, followed by multiple sclerosis treatment Kesimpta. The fastest growers were Scemblix, for a type of leukaemia, and cholesterol drug Leqvio, helped by its inclusion in China's national reimbursement list. Heart failure drug Entresto went the other way.

MedicineQ3 salesGrowth (cc)
Cosentyx$1,857m+9%
Kisqali$1,821m+37%
Kesimpta$1,484m+22%
Pluvicto$674m+20%
Scemblix$593m+67%
Leqvio$506m+63%
Entresto$1,165m-38%

Markets: indices, currencies and commodities

The del-desiran writedown

The reported figures carry the cost of September's setback. Del-desiran, a treatment for myotonic dystrophy type 1 that Novartis gained through its $12bn purchase of Avidity Biosciences, missed the main goal of the Phase III HARBOR trial. Novartis has now booked a $1.9bn partial impairment on the asset.

That charge, booked in research and development costs, took operating income down 59% to $1.84bn. With higher interest costs on top, net income fell 70% to $1.20bn. Earnings per share fell to $0.63 from $2.04. Core figures, which Novartis uses for its guidance, exclude the charge.

The company said it saw signs of clinical activity in secondary measures and is working through the development path with regulators. It also pointed to progress in the other Avidity programmes: del-zota, for a form of Duchenne muscular dystrophy, won FDA Priority Review in the quarter.

A share price that has already recovered

The HARBOR failure on 8 September followed within days a separate Phase III miss for pelacarsen, a heart drug, and the shares fell 10.89% that day. They lost 13.54% that week to close at CHF 112.04.

They have since risen in five of six weeks and closed on Friday at CHF 128.00, up 14.2% from that low and close to the CHF 129.58 they closed at on 4 September, the day Novartis announced the pelacarsen result. Some of the good news in today's figures may therefore already be expected.

What investors watch now

Swiss trading opens after this release, and the first test is whether the profit beat and guidance upgrade outweigh the size of the writedown. Beyond the session, investors will watch how fast generic competition eats into older brands next year, and whether Kisqali and Kesimpta can keep growing at this pace.

Capital returns are the other thread. Novartis still has up to $4.9bn left to buy under the $10bn buyback it announced in July 2025, while net debt rose to $37.4bn at the end of September from $21.9bn at the end of 2025, mainly because of acquisitions. Full HARBOR data are due at a medical congress, which will shape what del-desiran is still worth.

Sources

Related stories

Markets

Novartis Sinks 13.5% on Twin Trial Failures as Brent Breaks $100 and the ECB Hikes

Novartis fell 13.54% in the week to 11 September after two late-stage trial failures, while Brent jumped 8.65% to $104.61 a barrel and the ECB raised rates for the second time this…

Markets

Novartis Suffers Its Worst Day on Record, Down 10.9%, After Two Late-Stage Trial Failures

Novartis fell 10.89% to CHF 111.80 on 8 September, its worst day on record, after del-desiran, the lead drug from its $12bn Avidity deal, missed its main goal, days after…

Business

Novartis MS Pill Remibrutinib Beats Rival Drug in Two Late-Stage Trials

Novartis said its oral BTK inhibitor remibrutinib cut relapses more than Sanofi's teriflunomide in two Phase III trials of about 2,000 MS patients, with no liver safety signal.

Markets

Roche Shares Climb as Divarasib Cuts the Risk of Death by 44% in Lung Cancer

Roche shares opened about 1.5% higher on Monday after divarasib cut the risk of death by 44% against approved KRAS G12C drugs in a Phase III lung cancer trial, extending an 11.7%…

Markets

Bitcoin Falls to $62,000 as $2bn of Leveraged Bets Are Wiped Out in Sixth Weekly Loss

Bitcoin fell to about $62,000 at the weekend as $2bn of leveraged bets were liquidated, its sixth straight weekly loss. It was back near $65,000 on Monday, with $60,000 the next…

Markets

Copper Hits a Four-Month Low at $13,210 as AI Doubts Drag European Miners Down 2.3%

Copper fell to $13,210 a tonne on Monday, a four-month low about 10% below September's record, as AI doubts and weak Chinese data hit metals and Europe's basic resources shares…

Markets

Bessent Urges an Outside CEO for Nvidia as Shares Fall 4.1% Before Results

Treasury Secretary Scott Bessent wants Nvidia to hire an outside chief executive, the board is not discussing Jensen Huang's return, and the shares fell 4.1% on Monday, a day…

Markets

Chip Index Sinks 5.28% With All 30 Stocks Down, Dragging the Nasdaq 2.49% Before Nvidia

The Philadelphia Semiconductor Index fell 5.28% on Monday 16 November with all 30 members down, pulling the Nasdaq 2.49% lower and the Dow down 739 points before Nvidia reports.